Karen Tedesco, MD
Hematology & Oncology · Amsterdam, NYNPI 1083601124
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $343,183 of the $446,553 with a category attached, or 76.9%. 23 manufacturers reported payments, led by Daiichi Sankyo Inc. at 35.3% of the total. 2025 is the largest year on record at $114,201, more than ten times the $594 reported in 2019. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $1382.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$158K
- Gilead$97K
- AstraZeneca$91K
- Merck$53K
- Stemline Therapeutics Inc.$24K
- Lilly USA, LLC$8K
- plus $16K from 17 others
Across 216 payments — averaging $7270.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$600K
- Novartis$532K
- Gilead$186K
- Genentech, Inc.$114K
- Radius Health, Inc.$58K
- AstraZeneca$46K
- plus $34K from 5 others
What the payments were for
- Consulting fees$62,06714%
- Speaking & faculty fees$343,18377%
- Travel & lodging$31,0647%
- Food & beverage$9,9972%
- Education$2440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 98 | $157,769 |
| Gilead(2 entities) | 75 | $96,959 |
| AstraZeneca | 59 | $91,482 |
| Merck | 32 | $52,661 |
| Stemline Therapeutics Inc. | 18 | $24,160 |
| Lilly USA, LLC | 3 | $7,500 |
| Pfizer | 6 | $6,825 |
| GSK | 2 | $1,942 |
| Myriad Genetic Laboratories, Inc. | 6 | $1,516 |
| Seagen Inc. | 2 | $1,499 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,212 |
| Puma Biotechnology, Inc. | 1 | $1,000 |
| Amgen | 1 | $649 |
| Exelixis Inc. | 2 | $235 |
| Genentech USA, Inc. | 2 | $204 |
| Incyte Corporation | 3 | $166 |
| Clovis Oncology, Inc. | 4 | $135 |
| Tesaro, Inc. | 1 | $125 |
| Springworks Therapeutics, Inc. | 1 | $123 |
| Novartis | 2 | $113 |
| Astellas Pharma US Inc | 1 | $107 |
| Regeneron Healthcare Solutions, Inc. | 1 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$446,553 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 61 | $894,952 |
| Lenalidomide | 49 | $717,142 |
| IbrancePalbociclib | 11 | $197,515 |
| LynparzaOlaparib | 18 | $190,742 |
| CalquenceAcalabrutinib Maleate | 12 | $181,746 |
| BrukinsaZanubrutinib | 12 | $171,935 |
| Abiraterone Acetate | 22 | $142,050 |
| Imatinib Mesylate | 27 | $40,462 |
| EliquisApixaban | 42 | $29,663 |
| Exemestane | 69 | $9,531 |
| Anastrozole | 388 | $7,859 |
| Letrozole | 58 | $1,241 |
| Ondansetron OdtOndansetron | 50 | $724 |
| Dexamethasone | 71 | $594 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $7,500 | $895,03277 claims |
| AstraZenecaLynparza, Calquence | $91,482 | $372,48830 claims |
| PfizerIbrance, Eliquis | $6,825 | $227,17753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Amsterdam
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.